CYP450 inhibitor that increases amiodarone exposure. Avoid concomitant use.
Source: NLP:amiodarone hydrochloride
58 interactions on record
CYP450 inhibitor that increases amiodarone exposure. Avoid concomitant use.
Source: NLP:amiodarone hydrochloride
Inhibits CYP3A4 activity, increasing systemic budesonide exposure. Avoid ingestion with budesonide.
Source: NLP:budesonide
Strong CYP3A4 inhibitor that increases elinzanetant exposure, raising risk of adverse reactions. Avoid concomitant use.
Source: NLP:elinzanetant
CYP3A4 inhibitor increases risk of myopathy by reducing lovastatin elimination.
Source: NLP:lovastatin
Strong CYP 3A4 inhibitor; rare reports of serious adverse events with ergot alkaloids including vasospasm leading to cerebral ischemia and/or extremity ischemia.
Source: NLP:methylergonovine maleate
CYP3A4 inhibitor; simultaneous use with both CYP2D6 and CYP3A4 inhibitors should be avoided due to increased risk of proarrhythmia.
Source: NLP:propafenone hydrochloride
Grapefruit juice inhibits CYP3A4-mediated metabolism of sirolimus and must not be taken with or used for dilution of sirolimus.
Source: NLP:sirolimus
Strong CYP3A inhibitor that may increase tacrolimus concentrations and risk of serious adverse reactions including neurotoxicity and QT prolongation.
Source: NLP:tacrolimus
May increase axitinib plasma concentrations and should be avoided.
Source: NLP:axitinib
CYP3A4 inhibitor may increase codeine plasma concentrations and morphine levels, potentially causing fatal respiratory depression, particularly when added after stable dosing.
Source: NLP:butalbital, acetaminophen, caffeine and codeine phosphate
Moderate CYP3A4 inhibitor increases cilostazol exposure. Requires cilostazol dose reduction to 50 mg twice daily.
Source: NLP:cilostazol
Toxicities reported when colchicine is administered with grapefruit juice, a CYP3A4 inhibitor. Serious and life-threatening toxicity potential.
Source: NLP:colchicine
Moderate or strong CYP3A4 inhibitor; reduce EMFLAZA dose to one third of recommended dosage when used concomitantly.
Source: NLP:deflazacort
Strong CYP3A4 inhibitor increases erlotinib exposure, raising risk of exposure-related toxicity. Avoid co-administration or reduce erlotinib dosage if unavoidable.
Source: NLP:erlotinib
Avoid grapefruit juice due to increased simvastatin plasma levels and myopathy risk.
Source: NLP:ezetimibe and simvastatin
CYP3A4 inhibitor resulting in more than 2-fold increase in AUC and Cmax of felodipine without prolongation in half-life.
Source: NLP:felodipine
CYP3A4 inhibitor that increases fentanyl plasma concentration, resulting in increased or prolonged opioid effects, respiratory depression, and sedation.
Source: NLP:fentanyl
CYP3A4 inhibitor that increases fentanyl plasma concentration, resulting in increased or prolonged opioid effects and respiratory depression.
Source: NLP:fentanyl citrate
CYP3A4 inhibitor; concomitant use can increase plasma concentration of fentanyl, resulting in increased or prolonged opioid effects, respiratory depression, and sedation.
Source: NLP:fentanyl transdermal
Avoid grapefruit juice due to increased simvastatin plasma levels and risk of myopathy and rhabdomyolysis.
Source: NLP:simvastatin
CYP3A inhibitor that increases tolvaptan exposure. Patients should avoid grapefruit juice beverages.
Source: NLP:tolvaptan
Possible drug interaction with alprazolam based on clinical studies in other benzodiazepines. Caution recommended.
Source: NLP:alprazolam
Grapefruit juice may increase exposure of cabozantinib, increasing risk of exposure-related adverse reactions. Avoid coadministration or reduce CABOMETYX dosage.
Source: NLP:cabozantinib
CYP3A4 inhibitor that increases carbamazepine plasma levels. Close monitoring of carbamazepine levels and dosage adjustment may be required.
Source: NLP:carbamazepine
CYP3A4 inhibitor may increase plasma concentrations of estrogens and may result in side effects.
Source: NLP:conjugated estrogens and medroxyprogesterone acetate
Affects cyclosporine metabolism, increasing blood concentrations. Should be avoided.
Source: NLP:cyclosporine
CYP3A4 inhibitor that may increase plasma hormone concentrations of desogestrel and ethinyl estradiol.
Source: NLP:desogestrel and ethinyl estradiol
CYP3A4 inhibitor may increase dronabinol systemic exposure and adverse reactions; monitor for increased dronabinol-related effects.
Source: NLP:dronabinol
Can increase plasma concentrations of estrogen or progestin or both.
Source: NLP:drospirenone and ethinyl estradiol
CYP3A4 inhibitor that can increase plasma concentrations of estrogen or progestin or both.
Source: NLP:drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium
Can increase plasma concentrations of estrogen or progestin through CYP3A4 inhibition.
Source: NLP:drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Strong CYP3A4 inhibitor that increases encorafenib plasma concentrations and may increase adverse reactions. Avoid coadministration; if unavoidable, reduce encorafenib dose.
Source: NLP:encorafenib
CYP3A4 inhibitor that may increase plasma concentrations of estradiol and may result in side effects.
Source: NLP:estradiol
CYP3A4 inhibitor that may increase plasma concentrations of estrogens and result in adverse reactions.
Source: NLP:estradiol and norethindrone acetate
CYP3A4 inhibitor may increase plasma concentrations of estrogen or progestin, resulting in adverse reactions.
Source: NLP:estradiol and progesterone
CYP3A4 inhibitor may increase plasma concentrations of estrogens and result in side effects.
Source: NLP:estrogens, conjugated
Strong CYP3A4 inhibitor that may increase serum concentrations of etonogestrel.
Source: NLP:etonogestrel
May increase plasma estrogen and/or progestin concentrations through CYP3A4 inhibition.
Source: NLP:etonogestrel and ethinyl estradiol
Moderate CYP3A4 inhibitor. No dosing adjustments recommended in the presence of this substance.
Source: NLP:fesoterodine fumarate
CYP3A4 inhibitor may increase serum hydrocortisone concentrations and risk of adverse reactions; may require dose decrease.
Source: NLP:hydrocortisone
Grapefruit juice may increase plasma concentrations of imatinib; avoid concomitant use.
Source: NLP:imatinib
Grapefruit juice may increase plasma concentrations of imatinib; avoid grapefruit juice.
Source: NLP:imatinib mesylate
Moderate CYP3A4 inhibitor that increases ivabradine plasma concentrations. Avoid concomitant use.
Source: NLP:ivabradine
Grapefruit juice, a CYP3A4 inhibitor, may increase plasma hormone concentrations of COCs.
Source: NLP:levonorgestrel and ethinyl estradiol and ferrous bisglycinate
CYP3A4 inhibitor may increase plasma hormone concentrations.
Source: NLP:norethindrone and ethinyl estradiol and ferrous fumarate
CYP3A inhibitor that may increase systemic exposure of estrogen component.
Source: NLP:levonorgestrel and ethinyl estradiol
Inhibits CYP3A4 and increases nimodipine plasma concentration. Ingestion of grapefruit/grapefruit juice is not recommended while taking nimodipine.
Source: NLP:nimodipine
CYP3A4 inhibitor that may increase plasma hormone concentrations.
Source: NLP:norelgestromin and ethinyl estradiol
May increase systemic concentrations of norethindrone.
Source: NLP:norethindrone
CYP3A4 inhibitor may increase plasma concentration of estrogen or progestin and may result in adverse reactions.
Source: NLP:norethindrone acetate and ethinyl estradiol
CYP3A4 inhibitor that may increase plasma hormone concentrations of norethindrone and ethinyl estradiol.
Source: NLP:norethindrone and ethinyl estradiol
CYP3A4 inhibitor that may increase plasma hormone concentrations of ethinyl estradiol and norgestimate.
Source: NLP:norgestimate and ethinyl estradiol
Strong CYP3A inhibitor that increases paricalcitol exposure. Dose adjustment may be necessary; monitor iPTH and serum calcium.
Source: NLP:paricalcitol
CYP3A inhibitor that increases ranolazine exposure. Limit ranolazine to 500 mg twice daily.
Source: NLP:ranolazine
Moderate CYP3A inhibitor; recommended suvorexant dose is 5 mg, may increase to 10 mg if needed.
Source: NLP:suvorexant
Coadministration increased maximum plasma concentration by 25%, area under curve by 48%, and half-life by 18%.
Source: NLP:triazolam
May significantly increase verapamil concentrations (AUC increased 28-36%, Cmax increased 40-57%), though clinical consequences not expected.
Source: NLP:verapamil hydrochloride
CYP3A inhibitor not expected to have significant effect on prasugrel active metabolite pharmacokinetics.
Source: NLP:prasugrel